Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 — Abstract for Onxeo Validive® accepteret til mundtlig præsentation ved ASTRO’s årsmøde 2015

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an abstract supporting the clinical evaluation of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet developed for the prevention and treatment of chemo-radioation therapy-induced severe oral mucositis (SOM) in patients with head and neck cancer, has been accepted for oral presentation at the upcoming 57th American Society for Radiation Oncology (ASTRO) Annual Meeting, being held October 18-21, 2015 in San Antonio, TX.

In an oral presentation during the ePoster 16 Discussion Session “Head and Neck V” on Wednesday, October 21, Dr. Jordi Giralt, M.D., Ph.D., Head of the Radiation Oncology Service at Vall d’Hebron University Hospital in Barcelona, Spain, and investigator of the Validive® Phase 2 trial, will discuss compliance and patient acceptability of Validive® findings from the global Phase 2 randomized double-blind, placebo-controlled study.

Logistical details for the oral presentation and poster session include:

Title: Compliance and Patient Acceptability of Clonidine Mucoadhesive Buccal Tablet (Clonidine Lauriad) to Prevent Severe Radiomucositis in Head and Neck Cancer Patients

Presenting Author:

Jordi Giralt, M.D., Ph.D.

Head of the Radiation Oncology Service at Vall d’Hebron University Hospital, Barcelona, Spain

Oral ePoster 16 Discussion:

Head and Neck V

Presentation # 1139

Wednesday, October 21, 2015

10:45 a.m. – 12:15 p.m. CT

Room 102 A/B, Henry B. Gonzalez Convention Center

151019EN Onxeo ASTRO Validive

Paris (Frankrig), København (Danmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt selskab med speciale i udvikling af lægemidler til behandling af sjældne kræftsygdomme, har i dag meddelt, at et abstract, der understøtter den kliniske evaluering af Validive® (Clonidine Lauriad®), en mucoadhesiv tablet til oral indtagelse, der er udviklet til forebyggelse og behandling af svær oral mucositis (SOM) fremkaldt af radio-kemoterapi hos patienter med hoved-halskræft, er blevet accepteret tik en mundtlig præsentation ved det 57. årsmøde i American Society for Radiation Oncology (ASTRO), som afholdes i San Antonio, Texas den 18.-21. oktober.

Ved en mundtlig præsentation under e-poster 16 Discussion “Head and Neck V” onsdag d. 21. oktober, vil Dr. Jordi Giralt, M.D., Ph.D., der leder Radiation Oncology Service på universitetshospitalet Vall d’Hebron i Barcelona og er investigator i Validive® fase II-studiet, gennemgå resultaterne vedrørende ordinationsoverholdelse og patienternes sikkerhedsprofil med Validive® fra dette globale randomiserede dobbeltblindede, placebokontrollerede fase II-studie.

I denne mundtlige præsentation og poster-session indgår:

Titel: Compliance and Patient Acceptability of Clonidine Mucoadhesive Buccal Tablet (Clonidine Lauriad) to Prevent Severe Radiomucositis in Head and Neck Cancer Patients

Præsenterende forfatter:      Jordi Giralt, M.D., Ph.D.

Leder af Radiation Oncology Service på universitetshospitalet Vall d’Hebron i Barcelona

Oral ePoster 16 Discussion:

Head and Neck V

Presentation # 1139

Onsdag, d. 21. oktober 2015

Kl. 10.45-12.15

Lokale 102 A/B, Henry B. Gonzalez Convention Center

151019DK Onxeo ASTRO Validive